dexamethasone during the anesthetic (23.5%) or administer
ondansetron (5.9%).
Major progress
The opioid message is being heard, says Dr. Viscusi, pointing to
results that generally stand in stark contrast to what might have been
expected 15, 10 or even 5 years ago.
"People appear to be embracing the idea of giving multiple non-opi-
oids," he says. "And they're reaching into the more novel areas, like
ketamine and lidocaine infusion. We're getting there, especially when
it comes to embracing the idea that non-opioids have a role in post-
operative pain. The next step is to extend the multimodal arsenal to
pre-treatment. That should be the goal for those who put a lot of
effort into their pain protocols and want to have well-honed recovery
pathways."
OSM
1 2 6 • O U T PA T I E N T S U R G E R Y M A G A Z I N E • F E B R U A R Y 2 0 1 6
